Table 4.

Logistic regression of factors associated with any baseline metabolic monitoring.

				95% CI for OR
	B	P	OR	Lower	Upper
Children
Emergency room (ER) visit	1.24	0.048*	3.44	1.01	11.71
Second-generation antipsychotic (SGA) typea		0.027*
Risperidone	Refb	Ref
Quetiapine	0.83	0.305	2.28	0.47	11.03
Aripiprazole	2.01	0.003*	7.44	2.02	27.45
No. of psychiatry visits	0.11	0.296	1.11	0.91	1.36
Constant	–2.64	<0.001*	0.07
Adolescents
Duration of contact		0.006*
0-1 month	Refb	Ref
1-3 months	2.63	0.004*	13.81	2.31	82.43
3-6 months	1.66	0.106	5.28	0.70	39.75
>6 months	0.73	0.437	2.07	0.33	12.92
ER visit	–0.41	0.415	0.67	0.25	1.77
Hospital admission	0.13	0.799	1.14	0.41	3.19
Psychatric comorbidityc	–0.59	0.199	0.56	0.28	1.36
ADHD diagnosis	–0.66	0.190	0.52	0.19	1.39
SGA type	–0.36	0.157
Risperidone	Ref	Ref
Quetiapine	0.87	0.548	0.70	0.21	2.27
Aripiprazole	0.27	0.147	2.40	0.74	7.82
Olanzapine	1.17	0.751	1.31	0.24	7.07
On other meds	0.22	0.024*	3.23	1.17	8.94
No. of psychiatry visits	–3.39	0.001**	1.24	1.10	1.41
Constant		<0.001**	0.03

^aNo children on olanzapine had any baseline monitoring.

^b“Ref” is reference value for 4-level independent variable.

^cDefined as having more than 1 mental health diagnosis at baseline.

*Statistically significant at P ≤ 0.05.

**Statistically significant at P ≤ 0.001.